GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BAY-1021189 | MK-1242 | Verquvo®
vericiguat is an approved drug (EMA & FDA (2021))
Compound class:
Synthetic organic
Comment: Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator [4]. It was initially developed for potential to reduce mortality and morbidity associated with chronic heart failure with reduced ejection fraction.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes. US FDA (2021) | EU EMA (2021) |
IUPAC Name ![]() |
| methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate |
Synonyms ![]() |
| BAY-1021189 | MK-1242 | Verquvo® |
Database Links ![]() |
|
| CAS Registry No. | 1350653-20-1 |
| DrugCentral Ligand | 5439 |
| GtoPdb PubChem SID | 374883897 |
| PubChem CID | 54674461 |
| Search Google for chemical match using the InChIKey | QZFHIXARHDBPBY-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | QZFHIXARHDBPBY |
| UniChem Compound Search for chemical match using the InChIKey | QZFHIXARHDBPBY-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | QZFHIXARHDBPBY-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖|
Vericiguat (links to external site)
Cat. No. HY-16774 |